<SEC-DOCUMENT>0001628280-26-001369.txt : 20260108
<SEC-HEADER>0001628280-26-001369.hdr.sgml : 20260108
<ACCEPTANCE-DATETIME>20260108164624
ACCESSION NUMBER:		0001628280-26-001369
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260108
DATE AS OF CHANGE:		20260108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Quanterix Corp
		CENTRAL INDEX KEY:			0001503274
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				208957988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38319
		FILM NUMBER:		26520345

	BUSINESS ADDRESS:	
		STREET 1:		900 MIDDLESEX TURNPIKE
		CITY:			BILLERICA
		STATE:			MA
		ZIP:			01821
		BUSINESS PHONE:		617-301-9400

	MAIL ADDRESS:	
		STREET 1:		900 MIDDLESEX TURNPIKE
		CITY:			BILLERICA
		STATE:			MA
		ZIP:			01821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>qtrx-20260108.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b9ad9-2f8d-73fc-a24f-b66dfe2143c1,g:61eb35ea-b9a4-4ac2-a205-eb5e284d7b74,d:53623ecc7569407d88b1ff535179157b-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>qtrx-20260108</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-20">Quanterix Corp</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001503274</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="qtrx-20260108.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001503274</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-08</xbrli:startDate><xbrli:endDate>2026-01-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i53623ecc7569407d88b1ff535179157b_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 8, 2026</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">QUANTERIX CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-4">001-38319</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-5">20-8957988</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-6">900 Middlesex Turnpike</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-7">Billerica</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-8">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-9">01821</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:115%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-10">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-11">301-9400</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-12">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading symbol(s):</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">registered:</span></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">QTRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Emerging Growth Company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-19">o</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i53623ecc7569407d88b1ff535179157b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2026, Quanterix Corporation (&#8220;Quanterix&#8221;) issued a press release announcing certain executive transitions as described in Item 7.01 below (the &#8220;Release&#8221;). The Release also discusses Quanterix&#8217;s expectations regarding certain financial results for the fiscal year ended December 31, 2025.  A copy of the Release is furnished as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 of this Form 8-K (including the portion of Exhibit 99.1 that discusses Quanterix&#8217;s expectations regarding certain financial results for the fiscal year ended December 31, 2025) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the &#8220;Securities Act&#8221;) or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i53623ecc7569407d88b1ff535179157b_13"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2026, Masoud Toloue, Ph.D., President and Chief Executive Officer of Quanterix Corporation (&#8220;Quanterix&#8221; or the &#8220;Company&#8221;), entered into a separation agreement and release with the Company (the &#8220;Separation Agreement&#8221;), pursuant to which his employment as President and Chief Executive Officer of the Company has ended and he has resigned as a member of the Board of Directors (the &#8220;Board&#8221;), both effective as of January 19, 2026. In connection with his termination of employment, Dr. Toloue will receive severance benefits consistent with the termination-without-cause provisions of his employment agreement with the Company previously filed with the Securities and Exchange Commission. In addition, the Separation Agreement provides that (i) any outstanding but unvested portions of Dr. Toloue&#8217;s equity awards that would have vested on or prior to April 30, 2026 will accelerate and become fully-vested and exercisable on the effective date of Dr. Toloue&#8217;s separation, (ii) any such restricted stock units that vest in accordance with the preceding clause will be settled within 60 days following vesting, and (iii) any stock options, to the extent vested, may be exercised on or prior to December 31, 2026.  A copy of the Separation Agreement is filed as Exhibit 10.1 and is incorporated herein by reference. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Also on January 8, 2026, the Board appointed Everett Cunningham as President and Chief Executive Officer of the Company, effective January 19, 2026. Mr. Cunningham was also appointed to serve on the Board as a Class II director, with a term ending at the 2028 annual meeting of stockholders.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Cunningham has served as Chief Commercial Officer of Illumina, Inc. since June 2024.  Prior to that, he was Chief Commercial Officer of Exact Sciences Corporation from 2021 to 2024 and President and Chief Executive Officer of GE Healthcare&#8217;s U.S. and Canada region from 2019 to 2021.  Earlier, he held various senior leadership roles at Quest Diagnostics and Pfizer.  Mr. Cunningham serves on the boards of directors of Arvinas, Inc., a NASDAQ-listed company, and Visby Medical.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2026, the Company entered into an employment agreement with Mr. Cuningham (the &#8220;Employment Agreement&#8221;), in connection with his appointment as President and Chief Executive Officer effective as of January 19, 2026, which provides for an initial annualized base salary of $750,000 and eligibility for an annual performance bonus with an annual bonus target of up to 100% of his base salary.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Employment Agreement also provides that Mr. Cunningham will receive a sign-on cash payment of $600,000, payable within 30 days following his start date (the &#8220;Sign-On Cash Payment&#8221;). If Mr. Cunningham voluntarily terminates his employment with the Company without Good Reason (as defined in the Employment Agreement) within one year of the start date, Mr. Cunningham will be required to repay 50% of the Sign-On Cash Payment, and if his employment is terminated for Cause (as defined in the Employment Agreement) within one year of the start date, he will be required to repay the Sign-On Cash Payment in full.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with his appointment, Mr. Cunninham also received long-term equity incentive awards consisting of (a) restricted stock units (RSUs) covering 1,070,000 shares of Company common stock, subject to time-based vesting (the &#8220;Time-Based RSUs&#8221;) and (b) RSUs covering 813,750 shares of Company common stock, subject to performance-based vesting (the &#8220;Performance-Based RSUs&#8221;). </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Time-Based RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Cunningham&#8217;s start date. One-fifth of the Performance-Based RSUs will vest on the later of (i) the date that the volume weighted average price of the Company&#8217;s common stock on the Nasdaq Global Market (or other applicable national securities exchange) (&#8220;VWAP&#8221;) equals or exceeds $10 per share for 30 consecutive days prior to the second anniversary of Mr. Cunningham&#8217;s start date and (ii) the first anniversary of his start date, two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $15 per share for 30 consecutive days prior to the third anniversary of Mr. Cunningham&#8217;s start date and (ii) the second anniversary of his start date, and the remaining two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $20 per share for 30 consecutive days prior to the fourth anniversary of Mr. Cunningham&#8217;s start date and (ii) the third anniversary of his start date. In the event of a Change-in-Control (as defined in the Employment Agreement) in which the consideration payable to a holder of a share of the Company&#8217;s common stock equals or exceeds $10, $15 or $20, the corresponding tranche(s) of the Performance-Based RSUs will vest as of such Change-in-Control, and if the consideration payable to a holder of a share of the Company&#8217;s common stock is between $10 and $15 or between $15 and $20, then vesting shall be determined by straight line interpolation within the applicable tranche.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If Mr. Cunningham&#8217;s employment is terminated by the Company without Cause or he resigns for Good Reason, he will receive continued payment of his base salary for 12 months (the &#8220;Severance Period&#8221;), payment of an amount equal to his annual target bonus for the year of termination, acceleration of any of the unvested portion of the Time-Based RSUs that would have vested during the Severance Period, and subsidized health benefits during the Severance Period. If Mr. Cunningham&#8217;s employment is terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control, Mr. Cunningham&#8217;s base salary continuation will last for 24 months, all of his outstanding but unvested equity awards subject to time-based vesting will become fully vested, and his outstanding but unvested Performance-Based RSUs will remain eligible for vesting in connection with such Change-in-Control. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Receipt of the foregoing termination benefits will be subject to Mr. Cunningham&#8217;s execution of a separation agreement, including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Employment Agreement is filed as Exhibit 10.2 and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except for the Employment Agreement, there are no arrangements or understandings between Mr. Cunningham and any other person pursuant to which Mr. Cunningham was appointed as an officer or director. There are no family relationships between Mr. Cunningham and any director, director nominee or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. Cunningham has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K. </span></div><div id="i53623ecc7569407d88b1ff535179157b_105"></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On January 8,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> 2026</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, the Company issued the Release, which announced the appointment of Mr. Cunningham as President and Chief Executive Officer of the Company and the departure of Dr. Toloue. A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. </span></div><div id="i53623ecc7569407d88b1ff535179157b_16"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Exhibits</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-qtrxx20260108.htm">Separation Agreement by and between the Company and Masoud Toloue.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102-qtrxx20260108.htm">Employment Agreement by and between the Company and Everett Cunningham.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-qtrxx20260108.htm">Press Release dated January 8, 2026.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div><div id="i53623ecc7569407d88b1ff535179157b_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date: January 8, 2026</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">QUANTERIX CORPORATION</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Vandana Sriram</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name:</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Vandana Sriram</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-qtrxx20260108.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i3e19ca921ea2478d929e4ed26736578f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">January 8, 2026</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Masoud Toloue</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Dear Masoud&#58;</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Quanterix Corporation (the &#8220;Company&#8221;) acknowledges your efforts and contributions to the Company. This separation agreement and release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Separation Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) memorializes the terms of your resignation as of January 19, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Resignation Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Resignation.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You hereby resign from your position as an employee, President, and Chief Executive Officer of the Company, your membership on the Company&#8217;s Board of Directors, and any other positions that you may hold with the Company or any of its direct or indirect subsidiaries, effective as of the Resignation Date. For purposes of the severance benefits under Section 8 of your Employment Agreement with the Company, dated as of April 25, 2022, and amended as of April 9, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), your resignation will be treated as if you were entitled to severance thereunder (not in the context of a change in control of the Company). Your resignation is a &#8220;separation from service&#8221; for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Benefits.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 7 of your Employment Agreement, the Company will pay you (i) your base salary through the Resignation Date, (ii) the amount of any expenses properly incurred by you on behalf of the Company prior to the Resignation Date and not yet reimbursed&#59; and (iii) to the extent not yet paid or provided, any other amounts or benefits required to be paid or provided or which you have earned under any plan or agreement of or with the Company through the Resignation Date. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to the Accrued Obligations, and pursuant to Section 8 of your Employment Agreement and the terms of this Separation Agreement, the Company will provide you with the following benefits (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="margin-bottom:9pt;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.69pt">Continuation of your base salary for a period of twelve (12) months after the Resignation Date at the rate in effect on the Resignation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Salary Continuation Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; and such period the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:9pt;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.36pt">Continued eligibility for an annual bonus for 2025, with the amount of such annual bonus (if any) to be determined by the Board of Directors of the Company (or the Compensation Committee thereof) in its discretion, based on the achievement of the applicable performance metrics and the other terms and conditions of the Company&#8217;s annual bonus program and to be paid in 2026 at the same time annual bonuses are payable to the Company&#8217;s senior executive level employees&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.03pt">An amount equal to your applicable annual target bonus for 2026, paid in one lump sum on the Company&#8217;s next regularly-scheduled payroll date following the date that this Separation Agreement becomes effective (as described in Section 8 below)&#59; </font></div><div style="margin-bottom:9pt;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.69pt">If you timely elect health care continuation coverage available under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company will subsidize the cost of the regular premium for such benefits so that such cost is shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of (A) the end of the Severance Period or (B) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Health Benefits Continuation Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  In the event that the Company determines in its sole discretion that it cannot provide the foregoing Health Benefits Continuation Payments without potentially violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company shall, in lieu thereof, provide to you a taxable monthly payment in an amount equal to the Company&#8217;s portion of the monthly COBRA premium (as described above) that you would be required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether COBRA continuation coverage remains available and shall end on the earlier of (X) the end of the Severance Period, and (Y) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA&#59; and</font></div><div style="margin-bottom:9pt;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.02pt">Notwithstanding anything to the contrary in the equity plan or award agreements applicable to your previously granted stock options and restricted stock unit awards&#58; (A) any outstanding but unvested portions of such awards that would have vested on or prior to April 30, 2026 shall accelerate and become fully-vested and exercisable (in the case of stock options) as of the later of  (x) the Resignation Date, or (y) the date this Separation Agreement becomes effective (as described in Section 8 below), (B) any restricted stock units that vest pursuant to this Section 2(b)(v) shall be settled within 60 days following vesting (or, if any restricted stock unit award constitutes &#8220;nonqualified deferred compensation&#8221; subject to Section 409A, settlement shall occur on the existing settlement date if required in order to comply with Section 409A), and (C) any stock options, to the extent vested, may be exercised on or prior to December 31, 2026 (provided that in no event may a stock option be exercised after the term&#47;expiration date set forth in the applicable stock option agreement). Except as otherwise provided herein, any equity or equity-based awards shall be governed by the terms of the applicable Company equity plan and award agreement entered into in connection with such award.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Your entitlement to the Termination Benefits is subject to applicable law and you (A) resigning as described in Section 1 on (but not prior to) the Resignation Date&#59; (B) executing this Separation Agreement&#59; (C) continuing compliance with the covenants described in Sections 4 and 5 and agreeing to extend the &#8220;Non-Competition Period&#8221; as described in Section 4&#59; (D) returning Company Property as described in Section 6&#59; (E) cooperating to facilitate an orderly transition as described in Section 7&#59; and (F) not revoking this Separation Agreement during the Revocation Period described in Section 8(b).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Salary Continuation Payments will commence within 60 days after the Resignation Date and will be made on the Company&#8217;s regular payroll dates&#59; provided, however, that if the 60-day period begins in 2025 and ends in 2026, the Salary Continuation Payments shall begin to be paid in 2026. Notwithstanding the immediately preceding sentence, if you are a &#8220;specified employee&#8221; within the meaning of Section 409A, then no Salary Continuation Payment that constitutes &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A shall be made before the date that is six (6) months after the Resignation Date. Each Salary Continuation Payment shall be treated as a separate payment for purposes of Section 409A.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">No Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Except as described in this Section 2, you will have no rights to any further compensation under your Employment Agreement or this Separation Agreement. You are not eligible for benefits under any severance plan, policy, or program of the Company.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Release.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  In consideration of the Termination Benefits, you, for yourself, your heirs, administrators, representatives, executors, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Releasors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) hereby irrevocably and unconditionally release, acquit and forever discharge the Company and each of its subsidiaries, affiliates, shareholders, controlling persons, divisions, successors, assigns, trustees, officers, directors, partners, agents, and former and current employees, including without limitation all persons acting by, through, under or in concert with any of them (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Releasees</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> &#8221;), and each of them from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, remedies, actions, causes of action, suits, rights, demands, costs, losses, debts and expenses (including attorneys&#8217; fees and costs) of any nature whatsoever, known or unknown, whether pursuant to contract or in law or equity or otherwise and whether arising under any and all federal, state, local, county and&#47;or municipal statutes, regulations, rules, and&#47;or ordinances, including, without limitation the Civil Rights Acts of 1866 and 1871, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Genetic Information Non-Discrimination Act, the Uniformed Services Employment and Reemployment Rights Act of 1994, the Lily Ledbetter Fair Pay Act, the National Labor Relations Act, the Fair Labor Standards Act, the Family and Medical Leave Act, the Employee Retirement Income Security Act of 1974, COBRA, the Worker Adjustment and Retraining Notification Act, the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Fair Credit Reporting Act, the Occupational Safety and Health Act, the Older Workers Benefit Protection Act, the Equal Pay Act of 1962, the Massachusetts Fair Employment Practices Law, the Massachusetts Civil Rights Act, the Massachusetts Equal Rights Act, the Minimum Fair Wage Act, the Massachusetts Wage Act, the Massachusetts Equal Pay Act, the Massachusetts Parental Leave Act, the Massachusetts Sexual Harassment Statute, and&#47;or claims under the Constitutions of the United States and&#47;or the Commonwealth of Massachusetts, or any other unlawful criterion or circumstance, which the you had, now have, or may have or claim to have in the future against each or any of the Releasees by reason of any matter, cause or thing occurring, done or omitted to be done from the beginning of the world until the date of the execution of this release (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that nothing herein shall release the Company from (i) any obligation under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2 of this Separation Agreement, or (ii) any right of indemnification or to director and officer liability insurance coverage under any Company organizational documents or at law under any plan or agreement and applicable to you, including, without limitation, the Company&#8217;s bylaws and the Indemnification Agreement by and between you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Nothing in this release is intended to (x) interfere with your right to make a complaint or claim with a federal or state administrative agency including, for example, the National Labor Relations Board, the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Equal Employment Opportunity Commission or the Massachusetts Office of Diversity and Equal Opportunity, or (y) limit your right to receive and fully retain a monetary award from a government-administered whistleblower award program for providing information directly to a government agency. However, by executing this release, you hereby waive the right to recover in any proceeding that you may bring before the Equal Employment Opportunity Commission or any federal or state administrative agency or in any proceeding brought by the Equal Employment Opportunity Commission or any state human rights commission on your behalf. </font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Admission&#59; Company Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This release does not constitute an admission by the Company, or any of its subsidiaries, affiliates, divisions, trustees, officers, directors, partners, agents, or employees, or by you, of any unlawful acts or of any violation of federal, state or local laws. The Company acknowledges that none of the other members of the Board of Directors of the Company is presently aware of either (i) any outstanding obligations owed to the Company by you or (ii) any matter relating to your employment or board position that would not be covered by the Company&#8217;s indemnification obligations to you.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. You expressly waive any rights you may have under the statutes of any jurisdiction or common law principles of similar effect, to preserve Released Claims that you do not know or suspect to exist in your favor at the time of executing this release. You understand and acknowledge that you may discover facts different from, or in addition to, those which you know or believe to be true with respect to the claims released herein, and agree that this release shall be and remain effective in all respects notwithstanding any subsequent discovery of different and&#47;or additional facts. Should you discover that any fact relied upon in entering into this release was untrue, or that any fact was concealed, or that an understanding of the facts or law was incorrect, you shall not be entitled to any relief as a result thereof, and you surrender any rights you might have to rescind this release on any ground. This release is intended to be and is final and binding regardless of any claim of misrepresentation, promise made with the intention of performing, concealment of fact, mistake of law, or any other circumstances whatsoever. You acknowledge and agree that if you should hereafter make any claim or demand or commence or threaten to commence any action, claim or proceeding against the Releasees with respect to any cause, matter or thing which is the subject of the release under Section 3(a) of this Separation Agreement, this release may be raised as a complete bar to any such action, claim or proceeding.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">No Assignment of Released Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. You represent and warrant to the Released Parties that there has been no assignment or other transfer of any interest in any Released Claim.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Continuing Covenants.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You agree that the (i) Employee Confidentiality, Assignment and Non-Solicitation Agreement, dated as of April 25, 2022, and (ii) Employee Non-Competition Agreement, dated as of April 25, 2022 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) remain in full force and effect, and you agree to abide by the terms set forth therein. Further, as a condition of the Termination Benefits, you agree that the Non-Competition Period (as defined in the Employee Non-Competition Agreement) shall extend to the 12-month anniversary of the Resignation Date without you receiving any additional compensation other than the Termination Benefits.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Non-Disparagement.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">From and after the date of this Separation Agreement, (a) you will not make or publish any statements or comments (or authorize any statements to be reported as being attributed to you) that disparage, or take any other action that could injure the reputation, business or goodwill of the Company or any of its affiliates, or any of their respective employees, officers, directors, and agents, and (b) the Board of Directors of the Company will not direct anyone to disparage you.  This provision does not in any way restrict or impede you from exercising protected rights, and rights under the federal securities laws, including the right to report possible securities law violations to the SEC, without notice to the Company, to the extent that such rights cannot be waived by agreement. This provision also does not prevent you from complying with any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation, or order.  In addition, 18 U.S.C. &#167; 1833(b) provides, &#8220;An individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (x) is made (i) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney&#59; and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (y) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221;  Nothing in this Separation Agreement, any other agreement executed by you, or any company policies is intended to conflict with 18 U.S.C. &#167; 1833(b).</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Return of Company Property.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You agree that within three business days of the Resignation Date, you will return all Company Property or assets that you had or controlled during your provision of services as an employee or officer of the Company and any of its affiliates that have not previously been returned, and you will comply with any instructions related to deleting and purging duplicates of such Company Property. &#8220;Company Property&#8221; includes but is not limited to&#58; all tangible property&#59; your identification badge&#59; key fob&#59; notebooks&#59; laptop, desktop and handheld computers&#59; smartphones&#59; personal digital assistants (PDAs)&#59; secure ID cards&#59; keys&#59; external hard drives&#59; flash drives&#59; power and sync cables&#59; all originals and soft or hard copies of documents such as e-mails, facsimiles, handbooks, letters, manuals, or memoranda&#59; any emails, personal documents or materials containing confidential information of the Company or any of its affiliates, including personal notebooks or planners&#59; and any other Company- or Company affiliate-related communications, material, hardware, equipment or property. Notwithstanding the foregoing, you and the Company agree that you may retain your current laptop and cellular </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">telephone (including the telephone number), provided that, within five business days of your Resignation Date, you submit to the Company an affidavit certifying that you have permanently removed all Company-related information from the laptop and cellular telephone and not copied any such information onto any other device, platform or medium. You acknowledge and agree that you remain bound by confidentiality and non-use obligations with respect to any Company-related information.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Cooperation.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">For 60 days following the Resignation Date, you agree to reasonably cooperate and make yourself reasonably&#160;available&#160;to the Company on an as-needed basis in connection with the orderly&#160;transition&#160;of your duties without receiving any additional compensation other than the Termination Benefits. </font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">Acknowledgment and Revocation.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Acknowledgment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. You recognize that, in signing this Agreement, you are knowingly and voluntarily waiving your right to pursue any and all claims under the Age Discrimination in Employment Act, 29 U.S.C. &#167; 626 </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">et seq</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ADEA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising prior to the date that you execute this Agreement.  You understand that you may take twenty-one (21) days from the date this Agreement is presented to you to consider whether to execute this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Review Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and agree that any changes, whether material or immaterial, to this Agreement before you sign it will not restart the running of the Review Period. You have read this Separation Agreement, understand it, and voluntarily accept its terms, and you acknowledge that you have been advised by the Company to seek the advice of legal counsel before entering into this Separation Agreement, and have been provided with a period of twenty-one (21) days in which to consider entering into this Separation Agreement.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Revocation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. You have a period of seven business days following the execution of this Separation Agreement during which you may revoke this Separation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Revocation Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and this Separation Agreement shall become effective immediately following the expiration of the Revocation Period. If the Agreement is revoked by you in accordance with this Section 8(b), then you will waive all Termination Benefits and the terms of this Separation Agreement will be null and void.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">General Provisions.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the words &#8220;without limitation.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Separation Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Separation Agreement will remain in full force and effect. Any provision of this Separation Agreement held invalid or unenforceable only in part of degree will remain in full force and effect to the extent not held invalid or unenforceable.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Governing Law&#59; Entire Agreement&#59; Amendments&#59; Survival&#59; Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. This Separation Agreement will be governed by and construed and interpreted in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">accordance with the laws of the State of Massachusetts without reference to the principles of conflict of law. This Separation Agreement, your Employment Agreement, the Covenant Agreements, the Indemnification Agreement, and any long-term or equity-based award agreements by and between you and the Company constitute the entire agreement between you and the Company regarding the subject matter hereof and thereof and supersede any earlier agreement, written or oral, with respect thereto. This Separation Agreement represents your and the Company&#8217;s mutual agreement with respect to your compensation and benefits under your Employment Agreement, and in the event of any inconsistency between this Separation Agreement and your Employment Agreement, this Separation Agreement will control.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Pages Follow&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i3e19ca921ea2478d929e4ed26736578f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If you agree that this letter appropriately represents our understanding, please sign and return this letter, which will become a binding agreement on our receipt.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="padding-left:251.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.474%"><tr><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">QUANTERIX CORPORATION</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">William P. Donnelly</font></div></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">William P. Donnelly<br>Executive Chair </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">January 8, 2026</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Company Signature Page to Separation Agreement&#93;</font></div></div></div><div id="i3e19ca921ea2478d929e4ed26736578f_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AGREED AND ACCEPTED&#58;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Masoud Toloue</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:17.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Masoud Toloue</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">January 8, 2026</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;M. Toloue Signature Page to Separation Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102-qtrxx20260108.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ib17490450ce24ced87ebe7f9a92767ce_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">January 8, 2026</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Everett Cunningham</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58; Employment Agreement</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Dear Everett&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Quanterix Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is pleased to offer you the full-time position of President and Chief Executive Officer of the Company, reporting to the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You shall be nominated to be elected to serve as a member of the Board, effective as of your start date hereunder. Should any Board membership term of yours end or be scheduled to end while you are employed as President and Chief Executive Officer hereunder, the Company shall use its best efforts to nominate you for re-election to the Board for any succeeding Board membership term commencing during your employment. As with all Board members, your continuation as a director requires election as a director by the stockholders whenever directors are to be elected by the stockholders. Your service as a Board member shall be without further compensation. Should your employment with the Company cease for any reason, whether voluntary or involuntary, you shall immediately resign as a member of the Board and as a member of any committees thereof, without any further action required by the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) including board service, unless otherwise approved in writing by the Board, provided that you may engage in religious, charitable, or other community activities as long as such services or activities do not interfere or conflict with your obligations to the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Your start date will be on January 19, 2026 or such other date as may be mutually agreed by you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). We are excited about the prospect of you serving in this role.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company will pay you a salary at an annual rate of $750,000, paid in accordance with the Company&#8217;s standard payroll practices, subject to periodic review and adjustment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">upward, but not downward (except in the event of a salary reduction to all senior executive level employees as described in clause (ii) of Good Reason (as defined in Section 8 below), at the discretion of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You will be eligible to receive an annual performance bonus beginning with the Company&#8217;s 2026 performance year. Your annual bonus target will be up to 100% of your annual base salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The actual amount earned will be subject to the achievement of the metrics and goals established by the Company following consultation with you. The annual bonus will be subject to approval by and adjustment at the discretion of the Company, and the terms of any applicable bonus plan or award. The annual bonus shall be paid to you on the same schedule that bonuses are generally paid to the Company&#8217;s senior executive level employees.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You will be eligible to participate in the employee benefits and insurance programs generally made available to its full-time employees, including medical insurance, dental insurance, 401(k) Plan and match, Employee Stock Purchase Plan, Flexible Spending Account, term life insurance, and short- and long-term disability insurance, subject to the terms and conditions of such programs. Details of these benefits programs, including mandatory employee contributions, will be made available to you when you start. Additionally, you will be eligible for reimbursement of relocation expenses in connection with you joining the Company pursuant to the Company&#8217;s relocation policy for executives, with such adjustments as may be approved by the Chairman. You also will be eligible to receive paid vacation time pursuant to the Company&#8217;s unlimited time-off policy for exempt employees. Provisions of the Company&#8217;s vacation policy are set forth in the policy itself. The Company reserves the right to amend or terminate its programs, plans and policies at any time.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Sign-On Cash Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; As further inducement to joining our Company, you will be eligible to receive a sign-on cash payment in the amount of $600,000, payable within 30 days following your Start Date. You will be required to repay 50% of your sign-on cash payment should you voluntarily terminate your employment with the Company without Good Reason (as defined below) or 100% of your sign-on cash payment should the Company terminate your employment for Cause (as defined below), in either case within one year of your Start Date.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Sign-On Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; You will be eligible to receive sign-on equity awards consisting of 1,070,000 restricted stock units subject to time-based vesting (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time-Based</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and 813,750 restricted stock units subject to performance-based vesting (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Performance-Based RSUs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt">The Time-Based RSUs will vest in four equal annual installments on each of the first four anniversaries of your Start Date. </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">The Performance-Based RSUs will vest as follows&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.67pt">One-fifth of the Performance-Based RSUs will vest on the later of (i) the date that the volume weighted average price of the Company&#8217;s common stock on the Nasdaq Global Market (or other applicable national securities exchange) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">VWAP</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) equals or exceeds $10 per share for 30 consecutive days prior to the second anniversary of the Start Date and (ii) the first anniversary of the Start Date&#59;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:35.34pt">Two-fifths of the Performance-Based RSUs will vest on the later of (i) the date that such VWAP equals or exceeds $15 per share for 30 consecutive days prior to the third anniversary of the Start Date and (ii) the second anniversary of the Start Date&#59; and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:32.01pt">Two-fifths of the Performance-Based RSUs will vest on the later of (i) the date that such VWAP equals or exceeds $20 per share for 30 consecutive days prior to the fourth anniversary of the Start Date and (ii) the third anniversary of the Start Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In the event of a Change-in-Control (as defined below) in which the consideration payable to a holder of a share of the Company&#8217;s common stock equals or exceeds $10, $15 or $20, the corresponding tranche(s) of the Performance-Based RSUs shall vest as of such Change-in-Control, and if the consideration payable to a holder of a share of the Company&#8217;s common stock is between $10 and $15 or between $15 and $20, then vesting shall be determined by straight line interpolation within the applicable tranche (</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> if such consideration is $18, then 683,550 of the Performance Based-RSUs shall vest).</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Vesting of both the Time-Based RSUs and Performance-Based RSUs is subject to your continued service through the applicable vesting dates or vesting events, and any unvested portion of your awards will be forfeited upon your termination of service (except as provided in Section 8 below). Your awards will be subject to approval by the Board or the Compensation Committee thereof, your employment with the Company on the grant date and the terms of our 2017 Employee, Director and Consultant Equity Incentive Plan or 2025 Inducement Plan and the applicable award agreements. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Long Term Equity Incentive Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; You will also be eligible to receive additional awards under the Company&#8217; equity incentive plan, as the Compensation Committee may approve from time to time. The value of any awards will be discretionary and will be subject to your achievement of the metrics and goals established by the Company. Any equity grants will be subject to valuation methodologies and other terms and conditions applicable to other similarly situated executives of the Company, and will be subject to Compensation Committee approval.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">At-Will Employment&#59; Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Your employment is &#8220;at will,&#8221; meaning you or the Company may terminate your employment at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; defined as (a) your base salary through the date of termination&#59; (b) the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed&#59; and (c) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">to the extent not theretofore paid or provided, any other amounts or benefits required to be paid or provided or which you have earned under any plan or agreement of or with the Company through the date of termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Without limiting the at-will nature of your employment relationship, if the Company terminates your employment without Cause, or if you resign for Good Reason, the Company shall provide you with the following termination benefits (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Benefits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Salary Continuation Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Continuation of your base salary for a period of 12 months after the date of termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the salary rate then in effect.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. An amount equal to your applicable annual target bonus for the year of termination, paid in one lump sum on the Company&#8217;s next regularly-scheduled payroll date following the effective date of the separation agreement described below.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Health Benefits Continuation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;COBRA&#8221;), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of (i) the end of the Severance Period&#59; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Health Benefits Continuation Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Notwithstanding the above, if the Company otherwise determines in its sole discretion that it cannot provide the foregoing Health Benefits Continuation Payments without potentially violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the Company&#8217;s portion of the monthly COBRA premium (as described above) that you would be required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month and shall end on the earlier of (1) the end of the Severance Period or (2) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Acceleration of Time-Based RSUs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in the applicable equity plan or the award agreement applicable to your Time-Based RSUs, any outstanding but unvested portion of your Time-Based RSUs that would have vested during the Severance Period had you remained employed during such time shall accelerate and become fully-vested and exercisable as of the later of (i) the termination date, or (ii) the effective date of the separation agreement described below. Any unvested portion of the Performance-Based RSUs shall be forfeited upon the termination of your employment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Company terminates your employment without Cause, or if you resign for Good Reason, and the effective date of such termination occurs within the 90-day period immediately preceding or the 12-month period immediately following a Change- in-Control (such period the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change-in-Control Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and such termination a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change-in- Control Termination</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then the Termination Benefits shall be as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Severance Period as defined in (a) above shall be a period of 24 months after the date of termination.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(w)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">Your Health Benefits Continuation Payments shall be as provided in (c) above for a period of up to 12 months after the date of termination (notwithstanding that the Severance Period is 24 months).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">An amount equal to your annual target bonus for the year of termination, paid in one lump sum on the Company&#8217;s next regularly-scheduled payroll date following the effective date of the separation agreement described below.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(y)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding anything to the contrary in any applicable equity plan or award agreement, all of your outstanding but unvested equity awards subject to time-based vesting shall accelerate and become fully-vested and exercisable as of the later of (A) the termination date, (B) the effective date of the separation agreement described below, or (C) as of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">the Change-in-Control. Any unvested portion of your outstanding but unvested equity awards subject to performance-based vesting shall be forfeited upon the termination of your employment, except (i) that if the consideration payable to a holder of a share of the Company&#8217;s common stock upon the Change-in-Control equals or exceeds $10, $15 or $20, the corresponding tranche(s) of the Performance-Based RSUs shall vest (and if the consideration payable to a holder of a share of the Company&#8217;s common stock is between $10 and $15 or between $15 and $20, vesting shall be determined by straight line interpolation within the applicable tranche) as of the later of (x) the effective date of the separation agreement described below, or (y) the Change-in-Control, or (ii) as otherwise provided under the terms of the applicable equity plan or award agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(z)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt"> The Termination Benefits provided in connection with a Change-in-Control Termination pursuant to paragraphs (v), (w), (x) and (y) above shall be in lieu of, and not in addition to, the amounts referenced in paragraphs (a), (b), (c) and (d) above.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">You shall not have rights to any severance benefits under any Company severance plan, policy or otherwise in the event of a qualifying termination of employment either outside of or during the Change-in-Control Period (but shall have the rights to the Termination Benefits set forth in this Section 8).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless (a) within 60 days of your date of termination, you first (i) enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company, which shall include a general release in favor of the Company and related persons and entities and other standard provisions regarding confidentiality, cooperation, non-disparagement and the like as may be included in the Company's then current form of separation agreement and which may include a non-competition provision (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (ii) resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company&#59; and (iii) return all Company property and comply with any instructions related to deleting and purging duplicates of such Company property, and (b) you comply with the terms of your Restrictive Covenants Agreements (as defined below) or any other similar agreements with the Company. The Salary Continuation Payments shall commence within 60 days after the date of termination and shall be made on the Company's regular payroll dates&#59; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. In the event you miss a regular payroll period between the date of termination and the first Salary Continuation Payment, the first Salary Continuation Payment shall include a &#8220;catch up&#8221; payment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following (and, if applicable, that the Company has complied with the Cause Process (hereinafter defined) following the occurrence of a circumstance subject to the Cause Process)&#58; (i) theft, fraud, embezzlement, misappropriation of assets or property of the Company, or material violation of your Restrictive Covenants Agreements&#59; (ii) dishonesty, gross negligence, misconduct, gross neglect of duties, or breach of fiduciary duty to the Company&#59; (iii) violation of federal or state securities laws&#59; (iv) breach of an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">employment, consulting or other agreement with the Company&#59; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendere&#59; or (vi) continued, willful and deliberate non-performance by you of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause Process</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that (1) the Board has reasonably determined in good faith that a &#8220;Cause&#8221; condition has occurred&#59; (2) the Board has notified you in writing of the Board&#8217;s knowledge of the first occurrence of the Cause condition within 60 days of the first occurrence of such condition&#59; (3) you are provided a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause Cure Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to remedy the condition&#59; (4) notwithstanding such efforts, the Board reasonably and in good faith determines at the end of the Cause Cure Period that the Cause condition continues to exist&#59; and (5) the Board terminates your employment within 30 days after the end of the Cause Cure Period. If you cure the Cause condition during the Cause Cure Period, Cause shall be deemed not to have occurred. The Board shall not be required to follow the Cause Process as to those conditions which it reasonably determines in good faith cannot be cured within the Cause Cure Period. For the avoidance of doubt, you and the Company acknowledge and agree that clauses (i), (iii) and (v) cannot be cured and shall not be subject to the requirements of the Cause Process.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change-in-Control</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any of the following events&#58; (i) any &#8220;Person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the Company&#8217;s then outstanding voting securities&#59; (ii) a change in the composition of the Company&#8217;s Board of Directors occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors where &#8220;Incumbent Directors&#8221; means directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company)&#59; (iii) the consummation of a merger or consolidation of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation&#59; or (iv) the consummation of the sale or disposition by the Company of all or substantially all of the Company's assets. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that you have complied with the Good Reason Process following the occurrence of any of the following actions undertaken by the Company without your express prior written consent&#58; (i) the material diminution in your authority, duties and responsibilities or change in your reporting relationship such that you no longer report directly to the Board of Directors of the Company or that you are reporting to someone other than the Board of Directors&#59; (ii) a material reduction in your base salary (with any reduction in excess of 10% being deemed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">material), provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is pursuant to a salary reduction program affecting all of the similarly situated senior executive level employees of the Company and that does not adversely affect you to a greater extent than such similarly situated employees&#59; and (iii) a change in the geographic location at which you must regularly report to work and perform services (either in person or remote) of more than 30 miles, except for required travel on the Company's business&#59; or (iv) a material breach by the Company of any of its obligations to you under its employment agreements with you.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means that (1) you have reasonably determined in good faith that a &#8220;Good Reason&#8221; condition has occurred&#59; (2) you have notified the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition&#59; (3) the Company is provided with a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to remedy the condition&#59; (4) notwithstanding such efforts, you reasonably and in good faith determine at the end of the Cure Period that the Good Reason condition continues to exist&#59; and (5) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Section 280G</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">If any payment or benefit you would receive under this Agreement, when combined with any other payment or benefit you receive pursuant to a Change-in-Control (for purposes of this Section 9, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) would constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and, but for this sentence, be subject to the excise tax imposed by Code Section 4999 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then such Payment shall be either&#58; (i) the full amount of such Payment&#59; or (ii) such lesser amount (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reduced Payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">With respect to Section 9(a), if there is more than one method of reducing the Reduced Payment amount that would result in no portion of the Payment being subject to the Excise Tax, then the Payment shall be reduced or eliminated in the following order&#58; (i) cash payments&#59; (ii) taxable benefits&#59; (iii) nontaxable benefits&#59; and (iv) accelerated vesting of equity awards in a manner that maximizes the amount to be received by you.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">The determination of whether Section 9(a)(i) or (ii) applies, and the calculation of the amount of the Reduced Payment if applicable, shall be performed by a nationally recognized certified public accounting firm as may be designated by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting Firm</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Accounting Firm shall provide detailed supporting calculations to both the Company and you within 15 business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested by the Company, in a form that can be relied upon for tax filing purposes. All fees and expenses of the Accounting Firm shall be borne solely by the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">You may receive a Payment that is, in the aggregate, either more or less than the amount described in Section 9(a)(i) or (ii) (as applicable, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Overpayment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Underpayment&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">). If it is finally determined by a court of competent jurisdiction pursuant to a final non-appealable judgment, or the Internal Revenue Service, or by the Accounting Firm upon request by either the Company or you, that an Overpayment or Underpayment has been made, then&#58; (i) in the event of an Overpayment, you shall promptly repay the Overpayment to the Company, together with interest on the Overpayment at the applicable federal rate from the date of your receipt of such Overpayment until the date of such repayment&#59; and (ii) in the event of an Underpayment, the Company shall promptly pay an amount equal to the Underpayment to you, together with interest on such amount at the applicable federal rate from the date such amount would have been paid to you had the provisions of Section 9(a)(ii) not been applied until the date of payment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">It is intended that payments under this Agreement are exempt from, or comply with, Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder are exempt from or comply with Section 409A of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits will be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred will be made in accordance with Treasury Regulation Section 1.409A-1(h).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Anything in this Agreement to the contrary notwithstanding, if, at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then, to the extent necessary to comply with Section 409A of the Code, any payment or benefit that you become entitled to under this Agreement on account of your separation from service will not be payable and such benefit will not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment will include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code. In no event will the bonus payment described in Section 8(b) or 8(x) hereof, as applicable, be paid after March 15 of the calendar year following the calendar year in which your separation from service occurs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement will be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements will be paid as soon as administratively practicable, but in no event will any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year will not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">The Company makes no guarantee of any tax consequences with respect to any payment hereunder, including, without limitation, under Section 409A of the Code. The Company makes no representation or warranty and will have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section, and nothing herein shall be interpreted or construed to transfer any liability for any tax (including a tax or penalty due as a result of a failure to comply with Section 409A of the Code) from you to the Company or to any other individual or entity.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; All payments made by the Company to you under this Agreement shall be net of any tax or other amounts that the Company reasonably believes it is required to withhold under applicable law.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Guarantee of Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; The Company makes no guarantee of any tax consequences with respect to any payment hereunder, including, without limitation, under Section 409A of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; In no event shall you be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to you under any of the provisions of this Agreement and, subject to the aforesaid exception, such amounts shall not be reduced whether or not you obtain other employment.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Return of Company Property</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Upon termination of employment for any reason, you shall promptly return to the Company any keys, credit cards, passes, confidential documents or material, computer equipment, or other property belonging to the Company, and you shall also return all writings, files, records, correspondence, notebooks, notes and other documents and things (including any copies thereof) containing proprietary information or relating to the business or proposed business of the Company or its affiliated entities or containing any trade secrets relating to the Company or its affiliated entities. For purposes of the preceding sentence, the term &#8220;trade secrets&#8221; shall have the meaning ascribed to it under the Uniform Trade Secrets Act. You agree to represent in writing to the Company upon termination of employment that you have complied with the foregoing provisions of this Section.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Assistance with Claims</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; You agree that, consistent with the scheduling demands of your business and personal affairs, during and after your employment by the Company, you will assist the Company and its affiliated entities in the defense of any claims, or potential claims that may be made or are threatened to be made against any of them in any action, suit or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">proceeding, whether civil, criminal, administrative or investigative (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and will assist the Company and its affiliated entities in the prosecution of any claims that may be made by the Company or its affiliated entities in any Proceeding, to the extent that such claims may relate to your employment or the period of your employment by the Company. The Company agrees to reimburse you for your reasonable out-of-pocket expenses associated with such assistance, including travel expenses. Any such reimbursement shall be paid by the Company within no later than 30 days of the date on which you provide documentation to the Company that such expenses were incurred. In the event that the Company requires your extensive assistance outside of the one year period following the conclusion of your services to the Company as an employee, consultant or Board member, the parties will enter into an agreement to compensate you for your time incurred in fulfilling your obligations under this paragraph, other than time related to testifying as a fact witness in any proceeding (including, but not limited to, related activities preliminary and postliminary thereto).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Representation Regarding Other Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This offer is conditioned on your representation that you are not subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; As an express condition of your employment as the Company&#8217;s President and Chief Executive Officer, and in consideration of the payments and benefits provided under this Agreement, including but not limited to the base salary in Section 1, the bonus compensation in Section 2, the cash sign-on payment in Section 4, the grant of equity in Section 5 and eligibility for the Termination Benefits in Section 8 upon a qualifying termination of employment, you will be required to sign the Employee Non-Competition Agreement, and the Employee Confidentiality, Assignment and Non-Solicitation Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restrictive Covenants Agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Copies of the Restrictive Covenants Agreements will be provided to you concomitantly herewith. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Other Terms</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#58; </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt">As with all employees, our offer to you is contingent on your submission of satisfactory proof of your identity and your legal authorization to work in the United States. </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">The terms of this Agreement and the resolution of any dispute as to the meaning, effect, performance or validity of this amendment or the Agreement or arising out of, related to, or in any way connected with, this amendment, the Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute, and the prevailing party shall be awarded its attorneys&#8217; fees and costs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt">This Agreement, together with the Restrictive Covenant Agreements, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes in all respects all prior agreements between the parties concerning the subject matter hereof.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.7pt">The provisions of this Agreement shall survive the termination of this Agreement and&#47;or the termination of your employment to the extent necessary to effectuate the terms contained herein.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.03pt">No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to you at the last address you have filed in writing with the Company or, in the case of the Company, at the Company&#8217;s main offices, attention of the Chief Legal Officer.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:4.02pt">This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company (other than you).</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.69pt">Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreements) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its capital stock, properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and the Company&#8217;s respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:6.69pt">This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original&#59; but such counterparts shall together constitute one and the same document.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Legal Counsel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#58; By signing below, you acknowledge that you have been advised by the Company to seek independent legal counsel with respect to this Agreement and that you have had the opportunity to seek the advice of independent legal counsel prior to signing this Agreement. By signing below, you represent that you have read and understand all of the terms and provisions of this Agreement. This Agreement shall not be construed against any party hereof by reason of the drafting or preparation hereof.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We are excited about the opportunity to work with you at Quanterix. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer of employment by signing below and returning a copy to me.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We are confident that with your background and skills, you will have an immediate positive impact on our organization.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="ib17490450ce24ced87ebe7f9a92767ce_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:251.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.474%"><tr><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">QUANTERIX CORPORATION</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">William P. Donnelly</font></div></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">William P. Donnelly<br>Executive Chair</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">January 8, 2026</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AGREED AND ACCEPTED&#58;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Everett Cunningham </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:17.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Everett Cunningham</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">January 8, 2026</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature Page to Employment Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ex991-qtrxx20260108.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="id5d7078d93ca4470af27b807beb72b18_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:133%">Exhibit 99.1</font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#2f5496;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Press Release</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Planned Leadership Transition Positions Company for Growth</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BILLERICA, Mass., January 8, 2026</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; (BUSINESS WIRE) &#8211; Quanterix Corporation (&#8220;Quanterix&#8221; or the &#8220;Company&#8221;) (NASDAQ&#58; QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the &#8220;Board&#8221;) has appointed Everett Cunningham as the Company&#8217;s next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham&#8217;s start date, Dr. Toloue will remain available to the Company in an advisory capacity to support continuity and help ensure a smooth leadership transition. Contemporaneous with Mr. Cunningham&#8217;s appointment, Bill Donnelly, Executive Chair of the Board, will transition to his prior role as non-executive Chair of the Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since June 2024, Mr. Cunningham has served as Chief Commercial Officer of Illumina, a global leader in DNA sequencing and array-based technologies, where he was responsible for the company&#8217;s global commercial strategy and execution. During his tenure, Mr. Cunningham helped implement a redesigned commercial operating model to improve customer engagement and accelerate the commercialization of Illumina&#8217;s sequencing- and array-based solutions for genetic and genomic analysis. Previously, Mr. Cunningham served as Chief Commercial Officer at Exact Sciences, where he led marketing, sales, and customer service across the company&#8217;s portfolio of cancer screening and precision oncology diagnostics. Earlier in his career, he held senior leadership roles at Quest Diagnostics, GE Healthcare and Pfizer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We are excited to welcome Everett to Quanterix,&#8221; said Bill Donnelly, Executive Chair of the Board. &#8220;Throughout his career, Everett has demonstrated his ability to accelerate growth at both research tools and diagnostics companies, build high-performing commercial organizations and lead transformational change at scale. His deep understanding of our customers and markets and his track record of operational execution makes him exceptionally well suited to lead Quanterix in its next phase of growth.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Cunningham&#8217;s appointment follows a comprehensive search process, with the assistance of a leading executive search firm, as part of the Board&#8217;s long-term succession planning efforts.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Donnelly continued, &#8220;On behalf of the Board, I want to thank Masoud for his many contributions to Quanterix. Under his leadership, the Company significantly expanded its assay menu, entered adjacent markets, and built its Diagnostics business from the ground up, advancing the translation of its technology into clinical applications. These initiatives, together </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with the transformative acquisition of Akoya Biosciences, have positioned Quanterix for broader scientific impact, deeper clinical relevance and enhanced long-term value creation. To that end, we are pleased to share that we expect to exceed our guidance for revenue and cash for the full year 2025. We appreciate Masoud&#8217;s continued leadership during this transition and wish him every success in his next chapter.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Cunningham commented, &#8220;I am thrilled to join Quanterix as Chief Executive Officer at such an exciting time for the Company. With its differentiated technology platform, expanding portfolio and talented team, Quanterix is uniquely positioned to lead the next wave of innovation in advanced disease detection and therapeutic development. I look forward to working closely with the Board and my colleagues to advance the Company&#8217;s mission to improve health outcomes worldwide and deliver meaningful value for shareholders, patients, partners and other stakeholders.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Everett Cunningham</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Everett Cunningham, age 58, has served as Chief Commercial Officer of Illumina, Inc. (NASDAQ&#58; ILMN), a global leader in sequencing- and array-based solutions for genetic and genomic analysis since June 2024. Prior to Illumina, he was Chief Commercial Officer of Exact Sciences Corporation (NASDAQ&#58; EXAS), a leader in cancer screening and precision oncology diagnostics, from 2021 to 2024, overseeing global marketing, sales, and customer service functions. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before joining Exact Sciences, Mr. Cunningham served as President &#38; Chief Executive Officer of GE Healthcare&#8217;s U.S. &#38; Canada region from 2019 to 2021. Earlier, he served as Senior Vice President, Commercial at Quest Diagnostics Inc. (NYSE&#58; DGX), where he was responsible for global sales, marketing, and commercial operations from 2012 to 2019. And prior to that, from 1991 to 2012, Mr. Cunningham held a range of senior leadership positions at Pfizer Inc. (NYSE&#58; PFE), including Regional President, Established Products for Asia Pacific, Senior Director of Worldwide Learning and Development, Senior Director of Business Operations, Vice President Sales for U.S. Pharmaceuticals, and Vice President of Global Corporate Human Resources.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Cunningham currently serves on the boards of Arvinas, Inc. (NASDAQ&#58; ARVN) and Visby Medical. At Arvinas, he is a member of the Compensation and Audit committees. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Cunningham holds a bachelor&#8217;s degree in economics from Northwestern University.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In connection with his appointment, Mr. Cunningham will receive long-term equity incentive awards consisting of (i) restricted stock units (RSUs) covering 1,070,000 shares of Company common stock, subject to time-based vesting (the &#8220;Time-Based RSUs&#8221;) and (ii) RSUs covering 813,750 shares of Company common stock, subject to performance-based vesting (the &#8220;Performance-Based RSUs&#8221;). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Time-Based RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Cunningham&#8217;s start date. One-fifth of the Performance-Based RSUs will vest on the later of (i) the date that the volume weighted average price of the Company&#8217;s common stock on the Nasdaq Global Market (&#8220;VWAP&#8221;) equals or exceeds $10 per share for 30 </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">consecutive days prior to the second anniversary of Mr. Cunningham&#8217;s start date and (ii) the first anniversary of his start date, two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $15 per share for 30 consecutive days prior to the third anniversary of Mr. Cunningham&#8217;s start date and (ii) the second anniversary of his start date, and the remaining two-fifths will vest on the later of (i) the date that such VWAP equals or exceeds $20 per share for 30 consecutive days prior to the fourth anniversary of Mr. Cunningham&#8217;s start date and (ii) the third anniversary of his start date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity awards were granted under the Company&#8217;s 2025 Inducement Plan as an inducement material to Mr. Cunningham&#8217;s joining Quanterix in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by the Company&#8217;s Board of Directors.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Quanterix</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa&#174; technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company&#174;, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue&#8212;advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The financial results mentioned above are preliminary, unaudited results and may be subject to change as a result of the completion of Quanterix&#8217;s year-end financial reporting and auditing processes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix&#8217;s future business outlook, operations, strategy and financial performance, including statements related to our expectations regarding our financial results for the year ended December 31, 2025, about the development and commercialization of our products, and about the benefits we may realize from the acquisition of Akoya Biosciences Inc. Words and phrases such as &#8220;may,&#8221; &#8220;approximately,&#8221; &#8220;continue,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;anticipates,&#8221; &#8220;is likely,&#8221; &#8220;look ahead,&#8221; &#8220;look forward,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;strategy,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;potential,&#8221; &#8220;possible&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix&#8217;s future business, operations, strategy and financial performance&#58; risks related to the impact of recent U.S. government policies, including reductions in federal research funding and </font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased tariffs&#59; risks that we may not realize the expected benefits of our cost reduction actions&#59; risks associated with the anticipated timing for launch of, and features of, Quanterix&#8217;s next-generation instrument, Simoa One&#59; risks that Quanterix may fail to realize the anticipated benefits and synergies of its recent acquisitions of Emission, Inc. and Akoya Biosciences Inc.&#59; risk that integrating Quanterix&#8217;s business with that of Akoya could be more difficult, costly or time-consuming than expected&#59; Quanterix risks that Quanterix&#8217;s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect&#59; risks related to the restatement of Quanterix&#8217;s consolidated financial statements, including risks of increased costs and the increased possibility of legal proceedings and regulatory inquiries, sanctions, or investigation&#59; risks related to Quanterix&#8217;s ability to maintain effective internal control over financial reporting and disclosure controls and procedures, including its ability to remediate existing material weaknesses in its internal control over financial reporting and the timing of any such remediation&#59; risks related to defects or other quality issues in Quanterix&#8217;s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation&#59; risks related to Quanterix&#8217;s ability to retain and expand its customer base and achieve sufficient market acceptance of its products&#59; and other factors that may affect future results of Quanterix. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the &#8220;Risk Factors&#8221; sections contained therein, which are available on the SEC&#8217;s website at www.sec.gov.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix&#8217;s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Joshua Young</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(508) 846-3327</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ir&#64;quanterix.com</font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>qtrx-20260108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b9ad9-2f8d-73fc-a24f-b66dfe2143c1,g:61eb35ea-b9a4-4ac2-a205-eb5e284d7b74-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:qtrx="http://quanterix.com/20260108" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://quanterix.com/20260108">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="qtrx-20260108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="qtrx-20260108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://quanterix.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>qtrx-20260108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b9ad9-2f8d-73fc-a24f-b66dfe2143c1,g:61eb35ea-b9a4-4ac2-a205-eb5e284d7b74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_019b9ad9-2f8d-73a4-ada3-6daab354a991_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_019b9ad9-2f8d-71d0-8e23-da50c10b758b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_019b9ad9-2f8d-7641-bf00-6f772df3f137_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_019b9ad9-2f8d-7d79-8440-cf53e4448a16_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_019b9ad9-2f8d-7508-89b6-9c35ba329a69_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_019b9ad9-2f8d-7474-ab53-54ff21390515_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_019b9ad9-2f8d-7dbe-9d6d-f20ca0319d7a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_019b9ad9-2f8d-780c-aad2-0ec39be59afe_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_019b9ad9-2f8d-714f-9850-1b8ae223e3d7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_019b9ad9-2f8d-77c0-8235-0ba6ac0dc972_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_019b9ad9-2f8d-7c37-85e7-897ae585e8cc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_019b9ad9-2f8d-7338-81a4-a7efb43c0327_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_019b9ad9-2f8d-701b-be3c-b54ccf9dc470_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_019b9ad9-2f8d-7292-837f-8bdcbdca625a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_019b9ad9-2f8d-7ef6-b6b2-f6e0b2901642_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_019b9ad9-2f8d-7304-bc72-206a9b3d8774_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_019b9ad9-2f8d-7a77-af68-228b4f1bab3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_019b9ad9-2f8d-7cca-b8e7-72513f883f27_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_019b9ad9-2f8d-7093-b403-31461e2f5ee9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_019b9ad9-2f8d-7edc-a26f-defc219e6401_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_019b9ad9-2f8d-7660-867b-3d3b0be6fa74_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019b9ad9-2f8d-79d1-88c7-3dd03ac5324e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>qtrx-20260108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019b9ad9-2f8d-73fc-a24f-b66dfe2143c1,g:61eb35ea-b9a4-4ac2-a205-eb5e284d7b74-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://quanterix.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="qtrx-20260108.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://quanterix.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_019b9ad9-2f8d-777d-ba9e-dd5cae5b67f8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_DocumentType_019b9ad9-2f8d-777d-ba9e-dd5cae5b67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_019b9ad9-2f8d-7b0f-a0cc-4a5d7f0a4b68" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_DocumentPeriodEndDate_019b9ad9-2f8d-7b0f-a0cc-4a5d7f0a4b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_019b9ad9-2f8d-7c93-a137-d5422be8bdfa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityRegistrantName_019b9ad9-2f8d-7c93-a137-d5422be8bdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_019b9ad9-2f8d-7e67-93f1-e739c36dea79" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_019b9ad9-2f8d-7e67-93f1-e739c36dea79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_019b9ad9-2f8d-7d41-bda6-c53a038361c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityFileNumber_019b9ad9-2f8d-7d41-bda6-c53a038361c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_019b9ad9-2f8d-7b93-8434-f318ed332989" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityTaxIdentificationNumber_019b9ad9-2f8d-7b93-8434-f318ed332989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_019b9ad9-2f8d-7353-b1a4-e6335b4cad02" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityAddressAddressLine1_019b9ad9-2f8d-7353-b1a4-e6335b4cad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_019b9ad9-2f8d-75c2-bc7f-cf7bba06ba25" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityAddressCityOrTown_019b9ad9-2f8d-75c2-bc7f-cf7bba06ba25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_019b9ad9-2f8d-7f88-860f-941e969f456a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityAddressStateOrProvince_019b9ad9-2f8d-7f88-860f-941e969f456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_019b9ad9-2f8d-7124-8696-188696a6dc0b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityAddressPostalZipCode_019b9ad9-2f8d-7124-8696-188696a6dc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_019b9ad9-2f8d-7343-a1aa-152fba6acc2f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_CityAreaCode_019b9ad9-2f8d-7343-a1aa-152fba6acc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_019b9ad9-2f8d-7562-be25-779b94933620" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_LocalPhoneNumber_019b9ad9-2f8d-7562-be25-779b94933620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_019b9ad9-2f8d-77be-9e00-2337c3ca38db" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_WrittenCommunications_019b9ad9-2f8d-77be-9e00-2337c3ca38db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_019b9ad9-2f8d-76a4-a6a9-6cda76d7ee30" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_SolicitingMaterial_019b9ad9-2f8d-76a4-a6a9-6cda76d7ee30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_019b9ad9-2f8d-7f5a-b318-2518684b520f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_PreCommencementTenderOffer_019b9ad9-2f8d-7f5a-b318-2518684b520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_019b9ad9-2f8d-7d33-8c91-022b69c11392" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_019b9ad9-2f8d-7d33-8c91-022b69c11392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_019b9ad9-2f8d-7474-b6f6-ff1b12d7ccd6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_Security12bTitle_019b9ad9-2f8d-7474-b6f6-ff1b12d7ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_019b9ad9-2f8d-71cd-99bc-10bd787c10da" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_TradingSymbol_019b9ad9-2f8d-71cd-99bc-10bd787c10da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_019b9ad9-2f8d-7c03-ab69-b8a3b7f3a35a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_SecurityExchangeName_019b9ad9-2f8d-7c03-ab69-b8a3b7f3a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_019b9ad9-2f8d-7b81-a535-e7e184da74e9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityEmergingGrowthCompany_019b9ad9-2f8d-7b81-a535-e7e184da74e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_019b9ad9-2f8d-74f5-8596-ed17b08e9323" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_AmendmentFlag_019b9ad9-2f8d-74f5-8596-ed17b08e9323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_019b9ad9-2f8d-72fe-8819-824b4529a5e1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_019b9ad9-2f8d-7baa-ac02-d53df06580b4" xlink:to="loc_dei_EntityCentralIndexKey_019b9ad9-2f8d-72fe-8819-824b4529a5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Quanterix Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8957988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">900 Middlesex Turnpike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Billerica<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">301-9400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QTRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001503274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="qtrx-20260108.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://quanterix.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="qtrx-20260108.htm">qtrx-20260108.htm</File>
    <File>qtrx-20260108.xsd</File>
    <File>qtrx-20260108_lab.xml</File>
    <File>qtrx-20260108_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "qtrx-20260108.htm": {
   "nsprefix": "qtrx",
   "nsuri": "http://quanterix.com/20260108",
   "dts": {
    "inline": {
     "local": [
      "qtrx-20260108.htm"
     ]
    },
    "schema": {
     "local": [
      "qtrx-20260108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "qtrx-20260108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qtrx-20260108_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://quanterix.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qtrx-20260108.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "qtrx-20260108.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://quanterix.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-26-001369-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-001369-xbrl.zip
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M+S7N[,K I"R;D##.,,DII<G.D8D"OVO$^QPMT11N\?0<CKU,JX17/L\T6_P
M*#?+.@@Z(*C**_N=&DH%DRA(_0=:#'DT8-M3A@F.E/.JPR*A[[F HU(_$1.*
M9SA->2V'("UVZO2!^Z+*4E3P8\<YQA;@'R=E%*LMMT"YTR"%O,Q9RF9H3,QK
MMMGO[O9%4,+W-@R>F$D2-FD#[)#VA7/RQOR[ >X\Y=0C4YAT(C&FRW-F$J9(
M)25"*+"HW'2 IF#&9<J2170_5L2/_!L6B5=8F]1@0-5BEEP@]$[BE?D<)_W'
MDYR4?</;_UP%+PT1F W3U=9"5>OM4ZQBZ_6[HD0F9DL )/&L? ;J-*K814B
M,.C%<[(<Z:R,HDSWZ$T(L28;\SQO,0!9 $^L+- VF.4Y\CM;%LE'44S9IN?<
M2XL^@/IFE0.+INDM^:Q)L%/TK"K#:I&/5OD=C$5;@?F)K1TC-)JY!7,*"IFY
MQXN<0VLN]L=I./M[+B&1"4,F":BOQH<!'3:.*N#SNVX:O*X>E$FTI5UO^\P1
M] CC2N*M[D3922 DF,[$]L/.DE@G*BJSB+A^5TNG0TH0@G0A\!W@<)N-Z(];
M \_5WQ[N $;7O,NJDI)K$*G@G8,]9%XV,MUP/OQWNS =P<ZJQPX?$1 &E%4)
MFW.*4U[D*%?T2,. 5(T417F3R%WEO;R@V/Z*W#T*6F':2<<MDR#'2R^2!%#5
M,\$'S8N,'B/XPWJ#I$'3UI"A4M"[LQE[Z.(7[3@&><YP;N!"IQ4S9GSJ4$K<
M4'F<FD?4"Y50+I[8[_GDV1 ?9M4F!]W"J4<XF6R\MSEW'8A 8??]=P>'I^IA
MJAUZT9X!!LAT86<.LR,2;TP<N  H:9</B9J6A.V!EX=5HDZA<XZ%.WZ"SC3Z
MM<L2U9%N0*M;%&.1%S.**386Y-68F$U1REV33PGRAM$A D0YH2MWYT:'6/./
MC<L+-3[#C3;J<&Q1))(,M9I 6MJJ-\:0[7)"&XF')3REAUBZ[=5:CZN+V1H+
M;N0]SG]*#ITEC,T]# 3DU!I\FLA-DQX2G.*HZ.021="B!5IQ0#MZR=B LSLA
M1]37B/^\*_)=\GV7'!IG52<$CI9 X,"M] +!55:&P.71\8IR4@ AEXT>N-&7
MN$]\EBT(6-](HKI>L@ABC@.<!F1R7F?Y+ISR,$I1>;-#YP*"N/CX*+A%6AGO
M8+N&IYW9X.SFQ>($1,!R(ODC^;K[&^?K7@V3^H"6Q".Q879* 9'#7X[$(U7B
ML=AYGH;LW]B(:EN>P:L5>9<Y9A-E:HV+>[1V.DZHLJ@9[.VB,>:"QD-UBR85
M!Y:8M0 O\1<&;%D_NE,OX&YUOB!4U15M]1PGU "7% QX=*Z";IVHE%450'H
M5\<G.Y/Q'U*/IRIA?<G'J#P_<] E"UQ)XEJMW&/:!ND4CVR%H?1?*6M/KZ1E
M(@\5^FM:P0 4:OI!; ^>D6P!>@J:U(]M*[PQRB:7OH1,!:_'8[G;&Y82FZR#
M??IT2NR[0KPGQ\'*\^AJ7;<A'YMV4L=EL@$RD1$*U$0%PU2CB"K"J#*TG9@R
M7"1D>8H=.9J6B'(J1B N@**_X3]I%;J0:1(\.Z@S=\"8!F5PUG'9IQ1.;X;>
M-SYW?G]M<N>ON>YTP_C$AJ3..^"FXCR3>K+:;%L4CZ!<F) [N,PT(V[1(5I%
MXK<J&[E")YB5"NM2&*,MF %<:&<4: *H I!>C?5P9%K1/;!E$V4M9OJ0\6-1
M"%JQ#=O.V%>4S3IKG0#'9P@;6'6ALRNYU,:0;33,.&A9Y2%#B4) KI <CBE!
M/P0]@ZH*L%@*1(TQ8V(N]$GN?5?OV"QNE*,1A6SP-X56L612X=FZ0K0,E250
M2BWYE8!S:,LNIOKL._[@X:A-94N%DQ5<\DEC0M$FB)(RIXM@JN2E2P#'9"V2
M%:"\85D%.E%\NA/&BWQHRX?$*+3E:KXQGYL7!Q APW9(&$<1@(Z30E3;B1N"
M!;FJ2E< "H":;!ZZ EQ6A*ZB#O7'>$5@I,)#CW%X,(R,A$IPG%+3@2?$*SMP
MB))2$PD+B[@F )2"B;:$G,'Y[]$1T-S2B%1.),UM%)HL]'3B)DADY71EOH2X
M2IR/U2(8K  &*4UJ\>^LL/2^5 U=KX=0\A-%5B6(2).KF77&GA@IY9,(89H=
M7RX$#+<"U>@>3 9;L)V';27(U5KE]+,3XFJQ^YL#(KX6F5QEP7G9C%V1->IF
M $*F+C>UPN7A/U(H$#+8?DDN_PSX2H:;KO*2GB*G+$P\J7*=Z*G,Z,FJ9+BB
M(>L@:JI,,;'Z(84!F*!2%U-H9Q&)$B\"MI&):]9*SY*2#J=W-!C06GM'A[V.
M^(".1?'_;]\&;; UB'-P!@>=1^X>]_CN&3#!"XS+ZR   :*QHINXTI S8#TZ
MD3E'W'%0P,OZH3^#\"QU H*6$DMI/O3EM5X1GO][KHFII: ^4R&NC=^->[Y6
MJKXPMPNWQY^ =L5/*AVJ$NW,-U(;M![K][R3+!C$3W((AW*MW(G53] 8OGN#
MEC[YOJ.[R!YH03\#%24XDT(;(CQQZ1@QS%UJPZ;!VYQB56" 5 91,ZS[$-9-
M 50>BYV58-EGZ:\@%**= Y)KLL'?%248[TD+>#?2#&6N[.[[ATR%V?M[>WV^
M?U&DZ>X;L"@^BE\0S6_ ?J:D+00YMQ\ $%0H4J)$AR9$S@UL%\=09 ^6$FZ_
M3Y)JZL%Z(T>*2<4G/M3/H9AT6[1>NUKXPDO*5'#GYI#8;>5G$)S 0BL,!EE>
M680G5\@,"'E^DO>+!K1I8-$S_/:Y9^  )M6$7_D+!O&7#'_L7F-CBQZXDBC,
MYY&J^=2->L!Y_@)FIK6T\1OF0@V&PW*CE<!'#J$X>1L(#STI. 'S9C_<:423
M(K_G@X0!C65T0EL(XJI5#NQW5($0 Q1'EQRQ[T2;I)J@RPR]89QD@3-SS63:
M 7OXGHQPFHTZ4.#&_?*1R=,%YXL:520IY"VF3Y1.FII(-Q%!W@MJQP&::N[%
M#+"A$F4+23MGKJ-?"Z.-AIAQBOFQR*LIO=XGK--5DM7X O(/>H<87K@O3)9&
M^6\A.X["B114\0:&MIO1UV@][+1FC<LR9S"FK.!I<"#3^0@]E&.UGDX0:YP)
M6X+^Y CD6] $W3";$#3Y^F )CL,G"F<Q0T0[!.-^B6A! GI-\EIJ<^* -_%(
M4CK++VCXF.!C*_8 AIRQ6ENMN_+<RES_YD5OZGHP4A4[$ 9JPX^5HI/2V\X0
M>D(W;>0GAA#.< ;OJBN&WK9V'"7&S%SJ3GFO5,Z1$3<H%#RM,U]<NK.5)^*^
M<US0^[H] ]08 "LY*Q5.&+.;\&\SPNX[I+]SRQ["5GA@(C]BI"K8G[4D9B>
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M)TTWO%M1ODO54E%^UJ)0]2, V'C-^W!M-.]SWXYNTSZ1C=]ZGF\_NERW#:$
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M$.\HB>S,[0\Q47*%GI"JW(N-.]0ED_C"M>N@#$MS1$9TVI9L@[_,R8%0(YG
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MV]%WM,!!D-32H*\T7!^*.9H<.>R<"K&J&*0<_94W.D0&6UA3#H=9<'^H1IA
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M)%@B$CNS>6!H("BRLWEF)(G4( &9(T*M2;M;%//:'\^*U&14#+SDX'M54GF
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M5(B^O$> FB&GJF1X(-K=VBO4N""OVED8]76%[ ^G!N9ST.O=3GV[6*QR1$(
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M/-R-DL63\ <EG\@?LOQ?4$L#!!0    ( ,N%*%Q7^*&CMQ@  /N4   1
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MQ>)CL#9]'MSRN4+./,K)Y$W.(3][WOTL$5/6;-A--+WVX>K_AT*E04*%%I]
M)YGX*&@6]B%7.H,(E" ^6+7/ZVG>(%L.NA4 ;;^U_ZC6>\-#$Y]"MG3.J,X6
M[UDP1:T(6[K-IGV8/Z7/SN$N "^5@MKEH(&Q6 5VB^"@\WD8@I)V44F[H$\X
MP*ZB=*6P 4I#,^5*?Z3!&:W600/\/IW+WD&=;48?ZLZSL1L,P?$P&S%0$0,5
MYZ9* 7<69DIU &(6@STPJPM6"^Q&>7J%@9%&'M PZ6RX G7(\) 6TT;L1+@"
M2PE8RR&^=1J,'8-ZBO-D>#8K0';C5(:^FB"3$!1._)&?L%ZOX9"(45(^JQ^&
M-H!M!<P&3&U^0\-6D/#EI0H7Q0_S^UQP40GAYOLPQ[QY@<).49&!S,-S=Z;H
M8(%?R80G+[;$NQAZ" ("-B,!0@MXR<LD<^P'PC-R29T"# %S($BIY#"DN[&7
M4!+Z<H-\UV7UZ+> C9A*1_^!(1#QX'N!ST=^H'NG\8!I2D^A#K.7A@Z_3,:"
M")9E#U</T9BI"%E;"Y [3:69+S8ISWT9A]4QX"=B.I$&:XB:!"M21(*\!#P(
M,S('U=S%J:G4!;1H9E>Q3S:TE:W:BQNHSAT&ZD3$7":II/CHB2]A,2.ID)$#
M(]F?J!A0JD-V&AAI*S<]9,=Q'/EA0HE >++Z'OH_(E0<FL_9L92X--A:537_
MUHW@1ZZBU&-7,'HJZNQBTCAIU#&CJNC.&E+<@XDO4#]E1LWP!MFUG0W--H1Y
M;!S1;+O U@AUHA*6+P)95R@,ND=^+87.[>*$,M.;7T^6>>.+>S)_^SA[NQBJ
M[#Q1V)VAFA9T2$*/HS;G0GD*Y!F27L67X %^@1U=A]HN<C;5ZM:\^&,$NGM1
MW,MDT.-BWB!1$R;&8Q1]F 0GH<U6U>GI96VP,RQX"D.S08A/2!^P%R!O7N=6
MD%MG)[)AI ":!V@W7($C* %>$E[R!3HT%&,Z. LV!_, P)A\!4H]6_AEE":6
MR]$G+DKD<,AE+N?KNK*6,?K#NF"/;$[1HJ1MD<>Y>BV.\1 #T"/2ID"_M"H.
MF2^MM.G8\7=UE5^:D+N-9F"48OW?C5!H+HRU)D(*?A4V^8_43^8,#R1ZILO;
M* U "C@PTO2!G)=8YHQ[(0)M)?V M6R]<)KUX/:#@*.%(OI&PHVF8+C3()A;
MIA?\'E"F='U%#G$4ZMA#+AB>.>E?,<UB6]6!9$,SF1<0TT3Z%-10F)@ RG&]
MB1(<F$RD"_;3(X'(%R1&8='X(Z U)S)&*#Q)DBT=O+MOP[SFJE0_B;W"OW4B
M"":3S89&CV+B=CTS]Q1920PCZVS*YSB&8<,J:Y=QS?X*=*V4"<2Q)&\E#.O8
M6V!8]K:LPC%Z$U&%:2B4$]<F%>@]!64 :\H&:1C"NDWX]*&*LEX2UE7]]1'$
MMC3&+>I-G&<Q$RSK%?(F%WTS4]2O \S0L[,S -!:H]9-K(VT%&IG*HA.Z#T8
MKXL^7 J@>"H$!=M@IB2!DRCP*C' JU[0)=ZA_2%.$7?TXE#MER3_H+0Z9T&0
MHA*O@_9T&TSAX1[VSS0D)K5A]UQD6PLU0AV-V^T]7>H+&2Y=7U_R5P8)8QE-
ML6,'.\0!2'@V%J6?3MD_! ^2B<MEH=L^-RX;^DT><H]3R+88R^F9L1P@YI3N
M0)%$QD2 EK[A$NT-,"M$,@.Z D]-_)C)*$!;DP#<02UXXO/K, +%Y6H#=#&&
MU0&F+TLM<5UE CJ*R"S U+T"UXX!@-X RY7F.>A!=GY\>7+\JQ7XI.CST#0.
M]"]?@:;Y*#!(';PQJ:P"GV5SOXC]PCM @N&R8?*" UF\4P'Y_&I,Q$O^PL:Z
M[#X$5C>@,@<8Z"ESC!  ),'(/BD<8!^8=T2RB@?X.O3T_4''KL,J:!,?^-<^
MN;CSK >CJF(A*>Y P"P*06Q-.B%KH+],0!0$^4%IC+*/H<T,AI4&?F.RA'&7
MJK76-F(1U"U;DC*V!1<#8+D%TN!R!8O%YYG7^/V^3:M0QR\)81D(TUJ!,,A*
MNI138ZX%%P1[!\$?8.\7NO<BI'<V7I[<312D(70%S,H!-="QA)E7D++!V^RG
M*/+8$#PC=,$6$\')&H[M9G3AH2&*"1DK75!4KV3A"--A@'>E-L42D-2<=;1P
M$;2J(%TK,7_%"2@Y)D(GR0:$(A^3AHFX8][K)HRC(NQ^8]MCC?-74G3E-24,
MA_O&[ J/!5%X;6FHI#T:! *AUG;:MS$>H,%*F')<XSKL#"\_JUUH#[@16SMU
M^T"K-ZINTB$7(\:N+HE2NB2J'.H#OEBHK;S,7UC89<@VZT=ZC*/ET3=R*4:[
M]&4Q@Z[3JH.*W6;\DJZ]8QH7I5:KLWD4K^">H-/K3^H]7W[N:6X.?G&KMR3K
MN5<^CE*)NS6'%HSN9@\"$]@,=;%I=G[1ERK1[T!K'W\@ (R.W@V+RKX(&N2Z
MM,$^P<S&_CC)^ZL6?:UP:88& @=X+HLT!OCY^ 593#+3^ G-WQ3T-!&-[@I&
MGJXQO "8:\E]S"=6WK79.%559&PGO]D&%&$ "!JMNHY802-5Q)2RBMS=/([Y
MK]^.+W*U0ERFD#1&\@5HP^\=NRC8)/L%* %59(8:"3'$A?.$@1%X[I6X/]^(
M]UF89+>TC$M]+,(1P-BWD5ZL[=:#XD%(=R6]G6WI!?LLOY;<:IXMTXNOZ&*=
M*?=#RK,] 0>:6Z\X[C8"Z%_#@DHV+G* 0I\4+;LQ6):#%X/R#-K+PA]) &]V
M<VCEFZIT:D)FWS-U SDRIEB]#I7HX317-MFOE7NI3@(&WP&7ZV9<";8ZCG3@
M!G/J[D3LJ-V-]8]VTFA%5WB1H](GH1#]+)'<"A&2FL"A#'7%UQW]M:$VS-&%
MSEY2ZE+C8YVQQ!(TU) ,302=<Y=Q%/ <[)GU+&DYP[&W!F/7;H^UOL-H7ND8
M:7<">$YZ 7T^[9"7'*;"0\B<0ZRJ]$.L^"CYA4M^,_7B-!G=<:N6TD]9WD1?
MD%M*/17=H;L^Q1(_8[M!T BI:Q-NG'?MR6?Y^]S!*1(N]2)C8!([I;L*EI,7
MV??+2&)-NL)+95:KL$R1WCB DV''4"1C0O&X(D]TQ[L5WN]3KFY5[*="+2Z[
MNOF4RDMNY"+;;R Q 2<T)5FS;20!6 /?&WE9FTY:S!?=[? 8Y[7(!.5I$$HS
MWC7,7=I16TD39PJT*<N&K.!9M09]:QF/(>[P."EN\Y#B.B))+:5'<RG.<UG%
M^JP37!TF-%NP,GU=OI$EJ]7)7&>M=,!J<X3LN*R<7<,L)%7QZ(PW=@S3<0/N
M3Q6%-#F5<9,&B)/,6I6VR1M3^HL)NLH@WYH$7?,;+3([U?5"F?ZO8@GA!@ D
M"$I"P"H+-2U2ES)ENJ' (TMA/1(XM!OD(P&Z1;VY6B91E9G+DW*<SJ9$699&
MYJD.*F L9JAYQ'1L B#7Q(_OG5>1S,O^@IX0% F-'Q=O"UM.-RY-@.HRN:NS
M^3EM9>N"9A@/Y*&"#KT"!U=DUWAQX0BA,42<9$YQL'*T$:&<K]P@0B6L"\RH
M(JIMMTW9_E!<IP;*75H_5RG636NB.R]?Z(6UK>LKD7-"/YRP$\V55%9LSF^D
MWJKJ^,6(NU^N)> _SS+3&=-_A\\P.?-C"X][8<>&8]>7=AK559=JB;/LF2FM
M-@_Y8F'?LIIX8+U6%B_P%BH/\ZJ9QOIJ9YXDW%U;[/R-58DLESHC"N;DD8+R
M72!VH0@:54 9\Y3Y5-?.,7Z=%XX;G^+1RH\72V^7I_J@\M^[:WISG_TKBGL?
MKO7WJWY^#X_<6B! $NQ=7Z53D*_YX;,>L=S&:/3N,!K%(16Z@E8#'%T"2&*U
M7:7.,]*[Y@K'XA>2GG7D[+"8A5=F])OM1JN-Y&=,?$LW #WP@)[3;/1ZVUT1
M_O2W[73;C:;]Y_B]$"-JA.G.HV+7OMC],,],_PF= Z/RUFVN>BY=)N$LW"1Q
MUS42+T-W]4426$?[)'=K/!([[G*5QN.GX(F>FB=<4Q;9)^"!K6 ZO-*$"[UY
M#E]R;DS_YK*8.;9CX2\OS_)?7IXD4[R KJ*R>C0W]>S:SU]&X0M'44 G\*K+
MXY_HOK'GWP?-EU=Z?TG[]M+>K)+VRC#E/=*^6DG_;8L\>GQ_B?S;$_E>KU+!
M7] 9^"P:XI$[O53?_6W+LV.W7UZ<GYGF 191L@NLR3I#=X+KI-4)3[C^X:P=
M/'#E><6)KX3"1E2H\/N/PU^89WXT=I.?FWH[98U;1&AZK_2ND@=44CYC9.CR
M[*?SXZO/P]/+Q[U_ZF4#JW3Y6_DGM'7=&N6+\@/I&URB4*^ZG<I+@SFC$[B>
MCL<.4BD1EYC?@M;I*',L.=*_B#L2$QZ,LSH+G3;4#3""G>+)'.J6I\DDDECS
M\>" F_UV@D7M3J.-/\KS""&>_<;!P7:7/*^=5+O1L0]>^&KFU05]Y@@J_N1X
M?QEWW'/G\/[7_4S4\VD^^B6XNW^"NP2GEJQE[XZ;Q+8$)=LVVU#N'A<2O<CB
M_#CO;X$!7P<EJU8(*=E3>^Q?>,-@R-FE]"6?/N0GZ%[ :7NJ""U>7+OY[>5K
M(Y$/"$:^R/K_M?;+]_UO?W7]:UY?70Q1Y$]-,<0WY87MC2)O#O],DFEP]/]0
M2P,$%     @ RX4H7(8O7[=S @  . <  !$   !Q=')X+3(P,C8P,3 X+GAS
M9,U46V_;(!A]SZ]@?AZ^Y=(D:E)I[2I5RKJI:[6^31A_3E!M< $W[K\?$+,D
MS=(I>YJ?\,<YY[MPX/RBK4KT E(QP6=!$L8! DY%SOAR%CS<7^-Q<#'O]<X_
M8/SXZ6Z!K@1M*N :74H@&G*T9GJ%] K0#R&?V M!WTJB"R$KC.>.=BGJ5\F6
M*XW2.!UYF-^5TSB99!.23W!:C'-\UB\H)NF@P-EHE!>0)H,^33XNIZ,$LOX0
M"#;@ 1X0FAI8/,20#2$=#_*S[&S@1%LU570%%4&F-:ZFK9H%*ZWK:12MU^MP
MW0^%7$9I'"?1XY?%=P<-.FS)^-,>NLUDZ?']R&YG1(&'/VO9_H8_-X1KD*P-
MJ:@BVVN<Q., $:TERQH-UV8H5U"0IM2SH.$&7[*"06XF7H*=Z1Y@9UL3N01]
M2RI0-:'PMXSS'D)V"JRJA=2('_ .&V-<:<*I:6PSNH6@1#M''*78/^QYV(9P
MDN)^$K8J#Z)_J&$[W--J\+S3:W!B"FBX%"]1#LR.</CG].H8W"ZP7>SG))P+
M[?@VTL7JFO%"; (F9 N?^NKOH/!^/3!A9]ED,IE$;M?XSY&)I%*4\#XXJJ6H
M06H&:M? 3F EH3!6,S;&WCX_:PFAJ<1##A+L'X'=-AE &?^Z?A?;AKR$?JV-
MA#+G4,)F1/]S_R7)3NW?4* \L7%+O#?[B.6SP+^JA.>?N6;Z]8;;)]0--$ 6
M^G!W<^3>NPK>%?")?>H<"L:9,V?LO@3A[<.^LS1J:".'=O3.H[<J;_0;!?E7
M/G?KM];HR!WD'2(E)6W*TWG;LH[2NJ _@>Z&1OM7=/._<XU=8/,VS'N_ %!+
M P04    " #+A2A<!K..F2T)  !]5   %0   '%T<G@M,C R-C Q,#A?;&%B
M+GAM;,6<:V_;.!:&O^=7<+U?=H%AK/LE:#+H9MI!L)DV:%+,8!>+@*2H1*@L
M!;1R^_=+RG8B691,4K8*%*GC')_WO,=ZQ"/9TH=?7Q8Y>*)LF97%Z<P^MF:
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MDDT,4M=&EQY)C"DRW^A=)CXH+*HO:-'Y<,]U(QC9XFM](4VQYQ++=31GT+;
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M6KG6;JP&&WW=%;*G7:I+X_@F&*V)!OX-5L)A<R.6P)[$$Z]]P_:ZB]Z.^)'
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MQWW+[HY(-_KQ@ ;(4,Q!4TIBWL=P\8S[5ERPH7/1A[:#@.1<:Y>"XNG+;>,
M;W>"AA1)[+;PP"@-9:"$]DD/@.QPW0J.:.AP=-5T2&!,W,_W]C:_S[:[$"J"
MI(H,4B:24OA,"A+VA\5WQZV@X+\)%'OJ.20DZG71>WME\[LD4XUED>$<<>8V
M5W& (6:Q"4+6Q[YDM_=6<,2_"1Q=E!T2(5=Y48KTOV2Q:]F,2>!Z$3.$>?4E
MF%:^[(^/#=_MBEG^;X+'_K(>&(YJT#NW(';%38-J\^WTP"$Q4C"A%#'=BK _
M>&L'P(#+F7M+=^"45\]*TJM9GCVS?0J9F^V A"B*7'L04\J(WRGMVQ[;I7[
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MJK?ISX[^!U!+ 0(4 Q0    ( ,N%*%S_!5+(KB(  #R[   7
M  "  0    !E>#$P,2UQ=')X>#(P,C8P,3 X+FAT;5!+ 0(4 Q0    ( ,N%
M*%S]#>U4BC4  (Y- 0 7              "  >,B  !E>#$P,BUQ=')X>#(P
M,C8P,3 X+FAT;5!+ 0(4 Q0    ( ,N%*%S,?M)<?18  ,]2   7
M      "  :)8  !E>#DY,2UQ=')X>#(P,C8P,3 X+FAT;5!+ 0(4 Q0    (
M ,N%*%Q7^*&CMQ@  /N4   1              "  51O  !Q=')X+3(P,C8P
M,3 X+FAT;5!+ 0(4 Q0    ( ,N%*%R&+U^W<P(  #@'   1
M  "  3J(  !Q=')X+3(P,C8P,3 X+GAS9%!+ 0(4 Q0    ( ,N%*%P&LXZ9
M+0D  'U4   5              "  =R*  !Q=')X+3(P,C8P,3 X7VQA8BYX
M;6Q02P$"% ,4    " #+A2A<R^[@TNX%   =,0  %0              @ $\
ME   <71R>"TR,#(V,#$P.%]P<F4N>&UL4$L%!@     '  < TP$  %V:
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>qtrx-20260108_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="qtrx-20260108.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001503274</identifier>
        </entity>
        <period>
            <startDate>2026-01-08</startDate>
            <endDate>2026-01-08</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName contextRef="c-1" id="f-20">Quanterix Corp</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001503274</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-4">001-38319</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-5">20-8957988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-6">900 Middlesex Turnpike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-7">Billerica</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-9">01821</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-10">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-11">301-9400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-13">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">QTRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-19">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
